Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Citigroup Maintains Neutral on Rain Oncology, Lowers Price Target to $1

Author: Benzinga Newsdesk | September 18, 2023 09:46am
Citigroup analyst Yigal Nochomovitz maintains Rain Oncology (NASDAQ:RAIN) with a Neutral and lowers the price target from $1.5 to $1.

Posted In: RAIN

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist